VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders

Biomed Pharmacother. 2022 Jul:151:113099. doi: 10.1016/j.biopha.2022.113099. Epub 2022 May 17.

Abstract

Neuroendocrine regulatory polypeptide VGF (nerve growth factor inducible) was firstly found in the rapid induction of nerve growth factor on PC12 cells. It was selectively distributed in neurons and many neuroendocrine tissues. This paper reviewed the latest literatures on the gene structure, transcriptional regulation, protein processing, distribution and potential receptors of VGF. The neuroendocrine roles of VGF and its derived polypeptides in regulating energy, water electrolyte balance, circadian rhythm and reproductive activities were also summarized. Furthermore, based on the experimental evidence in vivo and in vitro, dysregulation of VGF in different neuroendocrine diseases and the possible mechanism mediated by VGF polypeptides were discussed. We next discussed the potential as the clinical diagnosis and therapy for VGF related diseases in the future.

Keywords: Diagnostic biomarkers; Neuroendocrine disorders; Neuropeptides; Neurotherapeutics; VGF.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Nerve Growth Factors / metabolism
  • Nervous System Diseases* / diagnosis
  • Nervous System Diseases* / drug therapy
  • Nervous System Diseases* / metabolism
  • Neuropeptides* / metabolism
  • Neuropeptides* / therapeutic use
  • Neurosecretory Systems
  • Prospective Studies
  • Rats

Substances

  • Biomarkers
  • Nerve Growth Factors
  • Neuropeptides
  • Vgf protein, rat